Humanetics Receives $3.8 Million from U.S. Department of Defense to Continue Dev

This award to Humanetics brings the total funding received by the Company from the Department of Defense (DoD) to just under $7 million. In the FY 2007 Defense Appropriations Act, Humanetics received $1.8 million. The prior year, the Company was awarded $1.25 million. Minnesota Senator Norm Coleman was instrumental each year in communicating the importance of the Company’s Medical Radiation Countermeasure program to Congress.

The 2008 funding will be used by Humanetics to continue development, clinical testing, regulatory approval, manufacturing and commercialization of a number of unique Medical Radiation Countermeasures. The Company’s lead candidate—BIO 300—is currently undergoing large animal efficacy and human safety trials. The Company also is working with several pre-clinical lead candidates which are showing promising early results.

Ronald Zenk, Humanetics’ President and CEO, said he is pleased with the continued federal funding because it underscores the seriousness of the threat posed by a terrorist or nuclear attack. “Any attack involving radioactive materials will be a devastating event, and there are no approved drugs to protect us from harm caused by ionizing radiation. We thank Senator Coleman for his ongoing support of this project, and are optimistic that our Medical Radiation Countermeasures will provide a safe, practical and effective treatment option for millions of military personnel and civilian populations worldwide,” he said.

A Multi-Year Partnership

BIO 300 was discovered by researchers at the Armed Forces Radiobiology Research Institute (AFRRI), a research institute within the Uniformed Services University of the Health Sciences (USU), and the National Institutes of Health (NIH). Humanetics obtained a worldwide exclusive license from The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., acting on behalf of USU and the NIH, to develop BIO 300 as an FDA-approved drug for the prevention of Acute Radiation Syndrome (ARS). ARS is a potentially fatal disease that occurs when the body receives a high dose of ionizing radiation, usually over a short period of time. Exposure to radiation causes a cascading deterioration of health leading to destruction of platelets and infection-fighting white blood cells in bone marrow.

Sources of ionizing radiation include: (i) contamination of food or water with finely powdered radioactive material than can be readily inhaled or ingested, (ii) placement of radiation material in public locations, (iii) detonation of radiological dispersal devices (“dirty bombs”), (iv) attacks on nuclear power facilities or high-level nuclear waste storage facilities, or (v) the worst possible scenario – detonation of a nuclear explosive device which, in addition to causing enormous destruction from blast and heat, would produce an intense burst of gamma radiation and large quantities of radioactive “fallout” affecting hundreds of thousands of people in the path of prevailing winds.

Over the past decade, the growing threat of terrorism has become a primary security concern in the United States and abroad. The number of known terrorist organizations with a global reach and the increased rate of proliferation and transfer of technical information through the Internet raise the possibility that attacks with radiological and nuclear weapons will occur on U.S. soil in the years to come. The situation is even more urgent overseas as tensions are building between hostile nations, many of which already have or are actively seeking nuclear weapons for targeted attacks against their neighbors using short-range missiles.

About Humanetics Corporation

Humanetics is a privately-held specialty pharmaceutical company headquartered in Minneapolis, Minnesota. The Company focuses on the discovery, development and commercialization of drugs for the prevention and treatment of diseases in categories with urgent and unmet needs. Humanetics has proprietary compounds in clinical and pre-clinical stages of development in the areas of Medical Radiation Countermeasures, Alzheimer’s disease and obesity. For more information, visit: .

This press release contains discussion of certain expectations regarding Humanetics’ future performance. These forward-looking statements are based on the Company’s current views and assumptions. Actual results could differ materially from these current expectations and projections, and from historical performance.